Zhengye Biotechnology Holding (ZYBT) Receivables - Other (2022 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Receivables - Other for 4 consecutive years, with $104052.5 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Receivables - Other rose 1.28% year-over-year to $104052.5 in Q4 2025; TTM through Dec 2025 was $104052.5, a 1.28% increase from a year earlier, with the FY2025 full-year figure at $3.3 million, up 829.17% from the prior year.
• Receivables - Other was $104052.5 for Q4 2025 at Zhengye Biotechnology Holding, up from $103000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $104052.5 in Q4 2025 and troughed at -$102498.9 in Q4 2023.
• A 4-year average of $41346.5 and a median of $102741.2 in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other slumped 18124.74% in 2023 and surged 200.24% in 2024, its largest moves.
• Over 4 years, Receivables - Other stood at -$562.42 in 2022, then tumbled by 18124.74% to -$102498.9 in 2023, then surged by 200.24% to $102741.2 in 2024, then increased by 1.28% to $104052.5 in 2025.
• The last three Receivables - Other figures came in at $104052.5 (Q4 2025), $103000.0 (Q2 2025), and $102741.2 (Q4 2024), per Business Quant data.